Hillis AL, Tamir T, Perry GE, Asara JM, Johnson JL, Yaron TM, Cantley LC, White FM, Toker A. Parallel phosphoproteomics and metabolomics map the global metabolic tyrosine phosphoproteome. Proc Natl Acad Sci U S A. 2024 Nov 19;121(47):e2413837121. doi: 10.1073/pnas.2413837121. Epub 2024 Nov 13. PMID: 39536083; PMCID: PMC11588116.

Hillis AL, Martin TD, Manchester HE, Högström J, Zhang N, Lecky E, Kozlova N, Lee J, Persky NS, Root DE, Brown M, Cichowski K, Elledge SJ, Muranen T, Fruman DA, Barry ST, Clohessy JG, Madsen RR, Toker A. Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer. Cancer Res. 2024 Oct 1;84(19):3250-3266. doi: 10.1158/0008-5472.CAN-24-0970. PMID: 39024548; PMCID: PMC11443248.

Mendez J, Toker A. Minimizing Shear Stress in Cell Signaling Studies. Curr Protoc. 2024 Mar;4(3):e1019. doi: 10.1002/cpz1.1019. PMID: 38506433.

Erickson EC, You I, Perry G, Dugourd A, Donovan KA, Crafter C, Johannes JW, Williamson S, Moss JI, Ros S, Ziegler RE, Barry ST, Fischer ES, Gray NS, Madsen RR, Toker A. Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation. Sci Signal. 2024 Feb 27;17(825):eadf2670. doi: 10.1126/scisignal.adf2670. Epub 2024 Feb 27. PMID: 38412255; PMCID: PMC10949348.

Madsen RR, Toker A. PI3K signaling through a biochemical systems lens. J Biol Chem. 2023 Oct;299(10):105224. doi: 10.1016/j.jbc.2023.105224. Epub 2023 Sep 9. PMID: 37673340; PMCID: PMC10570132.

Dibble CC, Barritt SA, Perry GE, Lien EC, Geck RC, DuBois-Coyne SE, Bartee D, Zengeya TT, Cohen EB, Yuan M, Hopkins BD, Meier JL, Clohessy JG, Asara JM, Cantley LC, Toker A. PI3K drives the de novo synthesis of coenzyme A from vitamin B5. Nature. 2022 Aug;608(7921):192-198. doi: 10.1038/s41586-022-04984-8. Epub 2022 Jul 27. PMID: 35896750; PMCID: PMC9352595.

Toker A. Can open science follow open access? J Biol Chem. 2022 Jan;298(1):101473. doi: 10.1016/j.jbc.2021.101473. Epub 2021 Dec 16. PMID: 34923237; PMCID: PMC8693261.

Hillis AL, Toker A. Lactate Lights up PI3K Inhibitor Resistance in Breast Cancer. Cancer Cell. 2020 Oct 12;38(4):441-443. doi: 10.1016/j.ccell.2020.09.011. PMID: 33049205.

Liu H, Paddock MN, Wang H, Murphy CJ, Geck RC, Navarro AJ, Wulf GM, Elemento O, Haucke V, Cantley LC, Toker A. The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer. Cancer Discov. 2020 Aug;10(8):1226-1239. doi: 10.1158/2159-8290.CD-19-1262. Epub 2020 Jun 8. PMID: 32513774; PMCID: PMC7415683.

Geck RC, Foley JR, Murray Stewart T, Asara JM, Casero RA Jr, Toker A. Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy. J Biol Chem. 2020 May 8;295(19):6263-6277. doi: 10.1074/jbc.RA119.012376. Epub 2020 Mar 5. PMID: 32139506; PMCID: PMC7212655.

You I, Erickson EC, Donovan KA, Eleuteri NA, Fischer ES, Gray NS, Toker A. Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling. Cell Chem Biol. 2020 Jan 16;27(1):66-73.e7. doi: 10.1016/j.chembiol.2019.11.014. Epub 2019 Dec 16. PMID: 31859249; PMCID: PMC6980747.

Toker A. Double trouble for cancer gene. Science. 2019 Nov 8;366(6466):685-686. doi: 10.1126/science.aaz4016. PMID: 31699922.

Guo J, Dai X, Laurent B, Zheng N, Gan W, Zhang J, Guo A, Yuan M, Liu P, Asara JM, Toker A, Shi Y, Pandolfi PP, Wei W. AKT methylation by SETDB1 promotes AKT kinase activity and oncogenic functions. Nat Cell Biol. 2019 Feb;21(2):226-237. doi: 10.1038/s41556-018-0261-6. Epub 2019 Jan 28. PMID: 30692625; PMCID: PMC6377565.

Toker A, Dibble CC. PI 3-Kinase Signaling: AKTing up inside the Cell. Mol Cell. 2018 Sep 20;71(6):875-876. doi: 10.1016/j.molcel.2018.09.006. PMID: 30241602.

Clement E, Inuzuka H, Nihira NT, Wei W, Toker A. Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors. Sci Signal. 2018 Mar 13;11(521):eaao3810. doi: 10.1126/scisignal.aao3810. PMID: 29535262; PMCID: PMC5902813.

Lien EC, Ghisolfi L, Geck RC, Asara JM, Toker A. Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT. Sci Signal. 2017 Dec 19;10(510):eaao6604. doi: 10.1126/scisignal.aao6604. PMID: 29259101; PMCID: PMC5808948.

Manning BD, Toker A. AKT/PKB Signaling: Navigating the Network. Cell. 2017 Apr 20;169(3):381-405. doi: 10.1016/j.cell.2017.04.001. PMID: 28431241; PMCID: PMC5546324.

Lien EC, Dibble CC, Toker A. PI3K signaling in cancer: beyond AKT. Curr Opin Cell Biol. 2017 Apr;45:62-71. doi: 10.1016/j.ceb.2017.02.007. Epub 2017 Mar 24. PMID: 28343126; PMCID: PMC5482768.

Brown KK, Spinelli JB, Asara JM, Toker A. Adaptive Reprogramming of <i>De Novo</i> Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer. Cancer Discov. 2017 Apr;7(4):391-399. doi: 10.1158/2159-8290.CD-16-0611. Epub 2017 Mar 2. Erratum in: Cancer Discov. 2017 Jul;7(7):782. PMID: 28255083; PMCID: PMC5380483.

Thomas C, Henry W, Cuiffo BG, Collmann AY, Marangoni E, Benhamo V, Bhasin MK, Fan C, Fuhrmann L, Baldwin AS, Perou C, Vincent-Salomon A, Toker A, Karnoub AE. Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers. Sci Signal. 2017 Feb 21;10(467):eaah4674. doi: 10.1126/scisignal.aah4674. PMID: 28223411; PMCID: PMC5858194.

Shimizu K, Fukushima H, Ogura K, Lien EC, Nihira NT, Zhang J, North BJ, Guo A, Nagashima K, Nakagawa T, Hoshikawa S, Watahiki A, Okabe K, Yamada A, Toker A, Asara JM, Fukumoto S, Nakayama KI, Nakayama K, Inuzuka H, Wei W. The SCFβ-TRCP E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis. Sci Signal. 2017 Jan 3;10(460):eaah4117. doi: 10.1126/scisignal.aah4117. PMID: 28049764; PMCID: PMC5215841.

Henry WS, Laszewski T, Tsang T, Beca F, Beck AH, McAllister SS, Toker A. Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling. Cancer Res. 2017 Feb 1;77(3):790-801. doi: 10.1158/0008-5472.CAN-16-2400. Epub 2016 Dec 9. PMID: 27940576; PMCID: PMC5290090.

Guo J, Chakraborty AA, Liu P, Gan W, Zheng X, Inuzuka H, Wang B, Zhang J, Zhang L, Yuan M, Novak J, Cheng JQ, Toker A, Signoretti S, Zhang Q, Asara JM, Kaelin WG Jr, Wei W. pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. Science. 2016 Aug 26;353(6302):929-32. doi: 10.1126/science.aad5755. PMID: 27563096; PMCID: PMC5326551.

Geck RC, Toker A. Nonessential amino acid metabolism in breast cancer. Adv Biol Regul. 2016 Sep;62:11-17. doi: 10.1016/j.jbior.2016.01.001. Epub 2016 Jan 21. PMID: 26838061.

Liu P, Gan W, Chin YR, Ogura K, Guo J, Zhang J, Wang B, Blenis J, Cantley LC, Toker A, Su B, Wei W. PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex. Cancer Discov. 2015 Nov;5(11):1194-209. doi: 10.1158/2159-8290.CD-15-0460. Epub 2015 Aug 20. PMID: 26293922; PMCID:

PMC4631654.

Toker A, Rameh L. PIPPing on AKT1: How Many Phosphatases Does It Take to Turn off PI3K? Cancer Cell. 2015 Aug 10;28(2):143-5. doi: 10.1016/j.ccell.2015.07.010. PMID: 26267528.

Brown KK, Montaser-Kouhsari L, Beck AH, Toker A. MERIT40 Is an Akt Substrate that Promotes Resolution of DNA Damage Induced by Chemotherapy. Cell Rep. 2015 Jun 9;11(9):1358-66. doi: 10.1016/j.celrep.2015.05.004. Epub 2015 May 28. PMID: 26027929; PMCID: PMC4464897.

Kaunisto A, Henry WS, Montaser-Kouhsari L, Jaminet SC, Oh EY, Zhao L, Luo HR, Beck AH, Toker A. NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer. Mol Oncol. 2015 Jun;9(6):1140-54. doi: 10.1016/j.molonc.2015.02.004. Epub 2015 Feb 19. PMID: 25735562; PMCID: PMC4439371.

Gasser JA, Inuzuka H, Lau AW, Wei W, Beroukhim R, Toker A. SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. Mol Cell. 2014 Nov 20;56(4):595-607. doi: 10.1016/j.molcel.2014.09.023. Epub 2014 Oct 30. PMID: 25458846; PMCID: PMC4255362.

Chin YR, Yuan X, Balk SP, Toker A. PTEN-deficient tumors depend on AKT2 for maintenance and survival. Cancer Discov. 2014 Aug;4(8):942-55. doi: 10.1158/2159-8290.CD-13-0873. Epub 2014 May 16. PMID: 24838891; PMCID: PMC4125464.

Toker A, Chin YR. Akt-ing up on SRPK1: oncogene or tumor suppressor? Mol Cell. 2014 May 8;54(3):329-30. doi: 10.1016/j.molcel.2014.04.020. PMID: 24813709; PMCID: PMC4089875.

Toker A, Marmiroli S. Signaling specificity in the Akt pathway in biology and disease. Adv Biol Regul. 2014 May;55:28-38. doi: 10.1016/j.jbior.2014.04.001. Epub 2014 Apr 19. PMID: 24794538; PMCID:PMC4062840.

Full PubMed Article List

https://pubmed.ncbi.nlm.nih.gov/?term=alex%20toker&sort=date